It was a pleasure to talk to Maria Oliva-Hemker (Johns Hopkins University School of Medicine, Baltimore, MD, US) around her presentation on ‘Treatment Updates: Where Do Immunomodulators Fit in Current Approaches to Therapy?’ which was presented at the virtual 2021 Crohn’s & Colitis Congress.
- What has clinical data taught us about the role of immunomodulator monotherapy for induction and maintenance of remission in paediatric IBD therapy? (0:15)
- At what stage would you advise a step up to anti-TNF therapy? (4:22)
- When should we use immunotherapy in combination with anti-TNFs agents? (5:31)
Disclosures: Maria Oliva-Hemker has nothing to disclose in relation to this video.
Support: Interview and filming supported by Touch Medical Media.
Filmed as a highlight of CCC 2021 (Virtual).
Share this Video
Related Videos In Inflammatory Bowel Disease
Detlef Schuppan, UEG 2021: Transglutaminase 2 Inhibitor in Celiac Disease
touchIMMUNOLOGY caught up with Prof. Detlef Schuppan (Mainz University Medical Center, Mainz, Germany) to talk about the results for the phase 2 study investigating the oral transglutaminase 2 inhibitor, ZED1227, in patients with celiac disease. His presentation entitled ‘ORAL INHIBITOR OF TISSUE TRANSGLUTAMINASE PREVENTS MUCOSAL DAMAGE IN CELIAC PATIENTS UNDERGOING GLUTEN CHALLENGE’ was given at […]
Detlef Schuppan, UEG 2021: Advances in the Management of Celiac Disease
It was a pleasure to catch up with Prof. Detlef Schuppan (Mainz University Medical Center, Mainz, Germany) following his presentations at virtual UEG week to discuss the current unmet needs in the treatment of celiac disease and advances being made in its management. His presentation entitled ‘ORAL INHIBITOR OF TISSUE TRANSGLUTAMINASE PREVENTS MUCOSAL DAMAGE IN […]
Marc Ferrante, UEG 2021: Filgotinib SELECTION Study Results in Ulcerative Colitis
touchIMMUNOLOGY were delighted to speak with Dr Marc Ferrante (University Hospital Leuven, Leuven, Belgium) about the results from the phase 2B/3 study of filgotinib in patients with ulcerative colitis as well as the use of the Partial Mayo Clinical Score in measuring outcomes. His presentation entitled ‘EARLY ACHIEVEMENT OF PARTIAL MAYO SCORE REMISSION AND IBDQ […]
Journal articles and more to your inbox
Get the latest clinical insights from touchIMMUNOLOGYSign me up!